Abstract:Background: To evaluate the value of gemcitabine combined with cisplatin (GP) as adjuvant chemotherapy in radical resection of non-small cell lung cancer (NSCLC). Methods: This study reviewed the 100 patients’ charts with radical resection of NSCLC treated with cisplatin/gemcitabine as adjuvant chemotherapy between June 2007 and December 2010 in CAMS (Chinese Academy of Medical Sciences). Results: Among the 100 cases, eighty-two (82%) was male and the median age was 59 years (range, 36-73 years). Forty-two (42%) patients were adenocarcinoma, while fifty-five (55%) were squamous cell carcinoma. Most patients had pathologic IIB (29%) and IIIA (44%) stage disease, whereas others were IA (2%), IB (14%), IIA (6%), and IIIB (5%). Surgical methods included sleeve resection (12%), pneumonectomy (14%), and lobectomy (73%).The completion rate of 4 cycles of chemotherapy was 85%, of which 76 case (76%) completed the planned full-dose chemotherapy. And the main reason for the reduction in gemcitabine doses in thirteen patients were grade 3/4 myelosuppression, mainly neutropenia and thrombocytopenia. The median dose and dose intensity were 8377.1 mg/m2 and 708 mg/(m2·week) for gemcitabine, and 293.38 mg/m2 and 25.24 mg/(m2·week) for cisplatin respectively. With good compliance to treatment, toxicities observed were tolerable and managable. During a median follow-up duration of 73.1 months, the median disease-free survival(DFS) was 33.8 months (95%CI: 15.938-51.676). Patients with the squamous cell carcinoma (HR 0.404, 95% CI 0.241-0.676, P = 0.001) and pathologic stage I (HR 4.379, 95% CI 1.721-11.142, P = 0.002) were associated with better DFS from univariate and multivariate analyses. The survival rate at 1 year, 2 years and 5 years was 94%, 77% and 55%, while the survival rate without recurrence was 64%, 53% and 39% respectively. Conclusions: As one of the adjuvant chemotherapy regimens, gemcitabine combined with cisplatin is well tolerated. Patients with squamous cell carcinomas or stage I can benefit from it better. Legal entity responsible for the study: None Funding: None Disclosure: All authors have declared no conflicts of interest.

Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Effect of DC-CIK Combined with Chemotherapy on Advanced Non-small Cell Lung Cancer and Its Influence on Immune Function

Impact of Dendritic Cells Combining with Cytokine-Induced Killer Cells Synergized Chemotherapy in Patients of Advanced Non-Small Cell Lung Cancer.

Analysis of the Association Between Prior Chemotherapy Regimens and Outcomes of Subsequent Anti-Pd-(l)1 Monotherapy in Advanced Non-Small Cell Lung Cancer.

A Prospective Study of the Efficacy of a Combination of Autologous Dendritic Cells, Cytokine-Induced Killer Cells, and Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients

Clinical trial of advanced non-small cell lung cancer by combination of gemci-tabine and cisplatin

The effect of chemotherapy combined with dendritic cells-cytotoxic T lymphocytes cells in patients with non-small cell lung cancer

ICI Plus Chemotherapy Prolonged Survival over ICI Alone in Patients with Previously Treated Advanced NSCLC.

Clinical Effects of Traditional Chinese Medicine Puls GP Regimen in Treatment of Advanced Non-small Cell Lung Cancer Patients

Effectiveness of immune therapy combined with chemotherapy on the immune function and recurrence rate of cervical cancer.

Dendritic Cells Combining with Cytokine-Induced Killer Cells Synergize Chemotherapy in Patients with Late-Stage Non-Small Cell Lung Cancer

Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.

Cellular Immunotherapy Combined with Platinum-Based Chemotherapy Prolongs Survival for Non-Small Cell Lung Cancer Patients.

A Retrospective Analysis to Explore the Value of Gemcitabine Combined with Cisplatin As Adjuvant Chemotherapy of NSCLC

Clinical observation of dendritic cells/cytokine-induced killer cells as maintenance therapy in patients with advanced non-small cell lung cancer

Clinical efficacy and safety evaluation of DC-CIK treatment combined with platinum-based chemotherapy for advanced non-small cell lung cancer

Gemcitabine Plus Oxaliplatin Combination in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Efficacy of DC-CIK-based immunotherapy combined with chemotherapy in the treatment of intermediate to advanced non-small cell lung cancer

Clinical Study on Gemcitabine Combined with Nedaplatin or Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

The Effect of PD-1 Inhibitor Combined with Chemotherapy on the Level of Peripheral Blood T Lymphocytes among Patients with Non-Small-Cell Lung Cancer and Its Relationship with Prognosis